13-Mar-2026
Market Chameleon (Thu, 12-Mar 5:25 AM ET)
NEW parodontax Gum Strengthen & Protect Launches as a Daily Solution for Long-Term Gum Protection
Business Wire (Thu, 12-Mar 9:00 AM ET)
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health
Business Wire (Wed, 11-Mar 5:00 AM ET)
Study in Nature Medicine Finds Taking Centrum Silver Daily May Slow Biological Aging
Business Wire (Mon, 9-Mar 1:00 PM ET)
Business Wire (Tue, 10-Feb 10:01 AM ET)
PRNewswire (Tue, 6-Jan 9:18 AM ET)
Business Wire (Tue, 16-Dec 8:54 AM ET)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Haleon PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol HLN.
As of March 13, 2026, HLN stock price declined to $10.03 with 6,216,286 million shares trading.
HLN has a beta of 0.21, meaning it tends to be less sensitive to market movements. HLN has a correlation of 0.03 to the broad based SPY ETF.
HLN has a market cap of $44.68 billion. This is considered a Large Cap stock.
In the last 3 years, HLN traded as high as $11.42 and as low as $7.70.
The top ETF exchange traded funds that HLN belongs to (by Net Assets): PPH, QLTI, AVDE, AQEC, RGEF.
HLN has underperformed the market in the last year with a price return of +0.1% while the SPY ETF gained +21.4%. However, in the short term, HLN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.4% vs -2.6% return in SPY. But in the last 2 weeks, HLN shares have been beat by the market, returning -9.4% compared to an SPY return of -3.5%.
HLN support price is $9.89 and resistance is $10.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HLN shares will trade within this expected range on the day.